Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 3NIH 3INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Other hematologic neoplasm 2Lymphoid 2Gastrointestinal 2Thoracic 1Genitourinary 1CNS 1Breast 1

Conditions

Colorectal Neoplasms 114Neoplasms 37Neoplasm Metastasis 24Stomach Neoplasms 22Pancreatic Neoplasms 19Colonic Neoplasms 15Rectal Neoplasms 13Esophageal Squamous Cell Carcinoma 13Sarcoma 10Esophageal Neoplasms 10Carcinoma, Non-Small-Cell Lung 10Small Cell Lung Carcinoma 8Sarcoma, Ewing 8Breast Neoplasms 8Parkinson Disease 4, Autosomal Dominant Lewy Body 7Glioblastoma 7Ovarian Neoplasms 6Gastrointestinal Neoplasms 6Uterine Cervical Neoplasms 5Solid Tumors 5Recurrence 5Neuroblastoma 5Intestinal Neoplasms 5Digestive System Neoplasms 5Cholangiocarcinoma 5Advanced Solid Tumor 5Rhabdomyosarcoma 4Gastrointestinal Diseases 4Endometrial Neoplasms 4Digestive System Diseases 4

Interventions

Rituximab 130Cyclophosphamide 41Bendamustine Hydrochloride 39venetoclax 25fludarabine 25obinutuzumab 24Lenalidomide 23ibrutinib 22Gemcitabine 22Vincristine 20Prednisone 20tositumomab I-131 19Doxorubicin 19plerixafor 14Dexamethasone 14Granulocyte Colony-Stimulating Factor 12pirtobrutinib 11Brentuximab Vedotin 11glofitamab 10tocilizumab 9pembrolizumab 9ibritumomab tiuxetan 9Etoposide 9Azacitidine 9polatuzumab vedotin 8parsaclisib 8copanlisib 8acalabrutinib 8Drug Therapy 8ublituximab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, Non-Hodgkin × Irinotecan × Clear all
NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

Actuate Therapeutics Inc.

Phase 2 Active not recruiting
350 enrolled
BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT04553692 2025-03-28

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

IGM Biosciences, Inc.

Phase 1 Terminated
272 enrolled
GastrointestinalLymphoidOther hematologic neoplasmSarcoma

Chondrosarcoma, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡